World Alzheimer’s Day 2026: Is Clinical Research Ready for the Next Era of Alzheimer’s Trials? Alzheimer’s research is entering a new phase. Advances in biomarkers are making it possible to identify biological signs of the disease earlier, clinical trials are increasingly reaching people before significant cognitive decline, and the drug pipeline is expanding beyond its traditional focus on amyloid. These advances are changing not only how Alzheimer’s is understood and Read more
Rare Disease Recruitment Is Getting Harder. Is Türkiye Being Overlooked?  By Pelin Ozdemir | Senior CRA I, Cromos Pharma  Rare disease trials have a geography problem. The same limited patient populations are repeatedly pursued across established research markets, while potentially relevant populations elsewhere receive far less attention.  Türkiye deserves earlier consideration in rare disease country-selection strategies. Its distinctive disease epidemiology, national screening programs, expanding clinical Read more
Rejected Twice, Then Approved: What Replimune’s FDA Reversal Means for Drug Developers  On August 6, 2026, the FDA granted accelerated approval to Replimune’s Tudriqev (vusolimogene oderparepvec-wtpg, formerly RP1) in combination with nivolumab for adults with unresectable advanced cutaneous melanoma whose disease had progressed following anti-PD-1 therapy.  Under ordinary circumstances, another oncology approval might not have attracted unusual attention. But Tudriqev had already been rejected by the FDA. Read more
Clinical Research Focus. 56th Edition Clinical Research Focus featuring topical articles of interest to the clinical trial community. Explore the news of July 2026. Read more

Schedule a meeting

We are excited to connect with you, understand your goals, and explore how we can support your needs.

Contact us